| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S0140-6736(08)61236-2 |
| P8608 | Fatcat ID | release_j5ddg45hzrcbfigblqam7aisge |
| P698 | PubMed publication ID | 18707986 |
| P50 | author | Salim Yusuf | Q2214381 |
| Kenneth Dickstein | Q43248428 | ||
| Leopoldo S. Piegas | Q46209817 | ||
| Roland E. Schmieder | Q57071845 | ||
| Andrzej Budaj | Q60835867 | ||
| Janice Pogue | Q82061920 | ||
| P2093 | author name string | Koon K Teo | |
| Matyas Keltai | |||
| Kaj Metsärinne | |||
| Ali Oto | |||
| Aldo Maggioni | |||
| Xingyu Wang | |||
| Alexander Parkhomenko | |||
| Johannes F E Mann | |||
| Helmut Schumacher | |||
| Leanne Dyal | |||
| Matthew McQueen | |||
| Suphachai Chaithiraphan | |||
| Tage L Svendsen | |||
| ONTARGET investigators | |||
| P2860 | cites work | Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes | Q28188162 |
| Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy | Q29615215 | ||
| Adverse effects of combination angiotensin II receptor blockers plus angiotensin-converting enzyme inhibitors for left ventricular dysfunction: a quantitative review of data from randomized clinical trials | Q31132556 | ||
| Telmisartan, ramipril, or both in patients at high risk for vascular events | Q33156143 | ||
| Mechanisms of progression and regression of renal lesions of chronic nephropathies and diabetes | Q34331403 | ||
| Assessing kidney function--measured and estimated glomerular filtration rate | Q34535861 | ||
| Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis | Q36336393 | ||
| Systematic review: comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers for treating essential hypertension | Q36993966 | ||
| Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy | Q42164528 | ||
| Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. | Q43683472 | ||
| Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial | Q44280775 | ||
| Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis | Q44579295 | ||
| Progression of renal insufficiency in type 2 diabetes with and without microalbuminuria: results of the Heart Outcomes and Prevention Evaluation (HOPE) randomized study | Q44634431 | ||
| Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial | Q44950867 | ||
| Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern? | Q50657801 | ||
| The COOPERATE trial: a letter of concern | Q81245976 | ||
| Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease | Q81555894 | ||
| P433 | issue | 9638 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | multicenter clinical trial | Q6934595 |
| P304 | page(s) | 547-553 | |
| P577 | publication date | 2008-08-01 | |
| P1433 | published in | The Lancet | Q939416 |
| P1476 | title | Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial | |
| P478 | volume | 372 |
| Q84791530 | "Proteinuria" itself cannot be taken as a definite marker of improved renal function |
| Q37281600 | 2009 Canadian Hypertension Education Program recommendations: an annual update. |
| Q37253885 | 2009 Canadian Hypertension Education Program recommendations: the scientific summary--an annual update |
| Q33916665 | 2010 Canadian Hypertension Education Program (CHEP) recommendations: the scientific summary - an update of the 2010 theme and the science behind new CHEP recommendations |
| Q42849832 | 2010 guidelines of the Taiwan Society of Cardiology for the management of hypertension |
| Q51821764 | 2012 consensus document of the Italian Society of Hypertension (SIIA): strategies to improve blood pressure control in Italy: from global cardiovascular risk stratification to combination therapy. |
| Q56970511 | 2013 ESH/ESC Guidelines for the management of arterial hypertension |
| Q26764784 | 2013 Korean Society of Hypertension guidelines for the management of hypertension. Part II-treatments of hypertension |
| Q36572355 | 2013 Korean Society of Hypertension guidelines for the management of hypertension: part III-hypertension in special situations |
| Q92463069 | 2018 Korean Society of Hypertension Guidelines for the management of hypertension: part II-diagnosis and treatment of hypertension |
| Q64277075 | 2019 Chinese guideline for the management of hypertension in the elderly |
| Q37656205 | 7th Brazilian Guideline of Arterial Hypertension: Chapter 7 - Pharmacological Treatment |
| Q37656189 | 7th Brazilian Guideline of Arterial Hypertension: Chapter 8 - Hypertension and Associated Clinical Conditions |
| Q91656866 | A Primer on Quality Assurance and Performance Improvement for Interprofessional Chronic Kidney Disease Care: A Path to Joint Commission Certification |
| Q37492556 | A guide to the management of blood pressure in the diabetic hypertensive patient |
| Q92992168 | A meta-analysis of MDR1 polymorphisms rs1128503 and rs1045642 and susceptibility to hepatocellular carcinoma |
| Q39038570 | A perspective on chronic kidney disease progression |
| Q37936466 | A review of renal, cardiovascular and mortality endpoints in antihypertensive trials in diabetic patients |
| Q50995599 | A study of the natural history of diabetic kidney disease (DKD). |
| Q35247114 | ACE inhibitors and ARBs: one or the other--not both--for high-risk patients. |
| Q37759964 | ADQI 7: the clinical management of the Cardio-Renal syndromes: work group statements from the 7th ADQI consensus conference |
| Q34912750 | Active vitamin D treatment for reduction of residual proteinuria: a systematic review |
| Q47764360 | Acute kidney injury is a risk factor for subsequent proteinuria. |
| Q36323673 | Add-on Protective Effect of Pentoxifylline in Advanced Chronic Kidney Disease Treated with Renin-Angiotensin-Aldosterone System Blockade - A Nationwide Database Analysis |
| Q42933669 | Adding a statin to a combination of ACE inhibitor and ARB normalizes proteinuria in experimental diabetes, which translates into full renoprotection |
| Q37139028 | Addition of aliskiren to Angiotensin receptor blocker improves ambulatory blood pressure profile and cardiorenal function better than addition of benazepril in chronic kidney disease. |
| Q24657470 | Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy |
| Q33800185 | Additive effects of cilnidipine, an L-/N-type calcium channel blocker, and an angiotensin II receptor blocker on reducing cardiorenal damage in Otsuka Long-Evans Tokushima Fatty rats with type 2 diabetes mellitus |
| Q33783689 | Addressing the theoretical and clinical advantages of combination therapy with inhibitors of the renin-angiotensin-aldosterone system: antihypertensive effects and benefits beyond BP control |
| Q46143921 | Advances in hypertension and diabetes |
| Q34491934 | Advances in treatment of hyperkalemia in chronic kidney disease |
| Q38139240 | Aggressive blood pressure reduction and renin-angiotensin system blockade in chronic kidney disease: time for re-evaluation? |
| Q36493465 | Aging and antihypertensive medication-related complications in the chronic kidney disease patient |
| Q38426631 | Albuminuria Is an Appropriate Therapeutic Target in Patients with CKD: The Pro View |
| Q42449372 | Albuminuria indicates the pressure-associated injury of juxtamedullary nephrons and cerebral strain vessels in spontaneously hypertensive stroke-prone rats |
| Q35682234 | Albuminuria is Not an Appropriate Therapeutic Target in Patients with CKD: The Con View |
| Q34139070 | Aliskiren and valsartan combination therapy for the management of hypertension |
| Q38872400 | Aliskiren in Patients Failing to Achieve Blood Pressure Targets With Angiotensin Converting Enzyme Inhibitors or Angiotensin Receptor Blockers |
| Q84742919 | Aliskiren in combination with valsartan exerts synergistic protective effects against ventricular remodeling after myocardial infarction in mice |
| Q33756874 | Aliskiren, the first direct renin inhibitor: assessing a role in pediatric hypertension and kidney diseases |
| Q38645328 | Aliskiren: Just a New Drug for Few Selected Patients or an Innovative Molecule Predestinated to Replace Arbs and Ace-Inhibitors? |
| Q37444731 | Aliskiren: a novel renoprotective agent or simply an alternative to ACE inhibitors? |
| Q37794969 | Aliskiren: a review of its use as monotherapy and as combination therapy in the management of hypertension |
| Q30664624 | Aliskiren: review of efficacy and safety data with focus on past and recent clinical trials |
| Q36878533 | An additive effect of eplerenone to ACE inhibitor on slowing the progression of diabetic nephropathy in the db/db mice |
| Q38096442 | An evaluation of the latest evidence relating to renin-angiotensin system inhibitors |
| Q35453845 | An overview of candesartan in clinical practice |
| Q37982634 | An update on the pathogenesis and treatment of IgA nephropathy |
| Q37166953 | Angiotensin II and oxidative stress in the failing heart |
| Q84605482 | Angiotensin II receptor blocker and long-acting calcium channel blocker combination therapy decreases urinary albumin excretion while maintaining glomerular filtration rate |
| Q47913701 | Angiotensin II type 2 receptor in chronic kidney disease: the good side of angiotensin II? |
| Q34836649 | Angiotensin blockade in late autosomal dominant polycystic kidney disease |
| Q47257220 | Angiotensin receptor blockers are associated with lower mortality than ACE inhibitors in predialytic stage 5 chronic kidney disease: A nationwide study of therapy with renin-angiotensin system blockade. |
| Q37167598 | Angiotensin receptor blockers for the reduction of proteinuria in diabetic patients with overt nephropathy: results from the AMADEO study. |
| Q37928133 | Angiotensin receptor blockers: pharmacology, efficacy, and safety |
| Q34623871 | Angiotensin-(1-7) abolishes AGE-induced cellular hypertrophy and myofibroblast transformation via inhibition of ERK1/2. |
| Q64107111 | Angiotensin-converting enzyme inhibitors or angiotensin receptor blocker monotherapy retard deterioration of renal function in Taiwanese chronic kidney disease population |
| Q33836604 | Angiotensin-converting enzyme inhibitors, angiotensin receptor blockers and combined therapy in patients with micro- and macroalbuminuria and other cardiovascular risk factors: a systematic review of randomized controlled trials |
| Q28828825 | Anti-Diabetic Effect of Portulaca oleracea L. Polysaccharideandits Mechanism in Diabetic Rats |
| Q38014361 | Anti-fibrosis therapy and diabetic nephropathy |
| Q48164731 | Antialbuminuric effect of eplerenone in comparison to thiazide diuretics in patients with hypertension. |
| Q92536909 | Antifibrotic Roles of RAAS Blockers: Update |
| Q24202090 | Antihypertensive agents for preventing diabetic kidney disease |
| Q42688526 | Antihypertensive efficacy of olmesartan medoxomil and ramipril in elderly patients with mild to moderate hypertension grouped according to renal function status : a retrospective analysis |
| Q37025604 | Antihypertensive efficacy of the angiotensin receptor blocker azilsartan medoxomil compared with the angiotensin-converting enzyme inhibitor ramipril |
| Q26865691 | Antihypertensive treatment and renal protection: the role of drugs inhibiting the renin-angiotensin-aldosterone system |
| Q24240164 | Antihypertensive treatment for kidney transplant recipients |
| Q42912298 | Antiproteinuric Effect of Cilnidipine in Hypertensive Japanese Treated with Renin-Angiotensin-System Inhibitors - A Multicenter, Open, Randomized Trial Using 24-Hour Urine Collection |
| Q37758534 | Application of direct renin inhibition to chronic kidney disease |
| Q37427247 | Are renin-angiotensin-aldosterone system blockers distinguishable based on cardiovascular and renal outcomes in nephropathy? |
| Q26863404 | Assessing the Validity of Surrogate Outcomes for ESRD: A Meta-Analysis |
| Q38148620 | Assessment of target organ damage in the evaluation and follow-up of hypertensive patients: where do we stand? |
| Q34042700 | Association of eGFR-Related Loci Identified by GWAS with Incident CKD and ESRD. |
| Q84230097 | Beneficial effect of aliskiren combined with olmesartan in reducing urinary protein excretion in patients with chronic kidney disease |
| Q38005041 | Beyond blood pressure: evidence for cardiovascular, cerebrovascular, and renal protective effects of renin-angiotensin system blockers |
| Q85562425 | Beyond the RAAS: dissecting the antifibrotic effects of vitamin D analogues |
| Q54264805 | Blockade of the Renin-Angiotensin System and the Risk of Acute Kidney Injury. |
| Q37511006 | Blocking the renin-angiotensin system: dual- versus mono-therapy |
| Q33683851 | Blood pressure and diabetic nephropathy |
| Q34219430 | Blood pressure and pulse pressure effects on renal outcomes in the Veterans Affairs Diabetes Trial (VADT) |
| Q90705376 | Bradykinin-Mediated Angioedema: An Update of the Genetic Causes and the Impact of Genomics |
| Q64092073 | Budget impact analysis of increasing prescription of renin-angiotensin system inhibitors drugs to standard anti-hypertensive treatments in patients with diabetes and hypertension in a hypothetical cohort of Malaysian population |
| Q33620560 | C-C motif-ligand 2 inhibition with emapticap pegol (NOX-E36) in type 2 diabetic patients with albuminuria |
| Q38859432 | Calibrating the impact of dual RAAS blockade on the heart and the kidney - balancing risks and benefits |
| Q26775106 | Can Aliskiren be Considered as a New Novel Drug for Hypertension? |
| Q85734297 | Can two be better than one? Dual RAS blockade in patients with type 2 diabetes and overt nephropathy in the age of ONTARGET and ALTITUDE |
| Q37893011 | Can we prevent or treat renal dysfunction in chronic heart failure? |
| Q24650348 | Canadian Cardiovascular Society Consensus Conference guidelines on heart failure, update 2009: diagnosis and management of right-sided heart failure, myocarditis, device therapy and recent important clinical trials |
| Q90321041 | Candesartan ameliorates vascular smooth muscle cell proliferation via regulating miR-301b/STAT3 axis |
| Q37919091 | Candesartan in the treatment of hypertension: what have we learnt in the last decade? |
| Q37534746 | Candesartan: widening indications for this angiotensin II receptor blocker? |
| Q61456524 | Cardiac hypertrophy as a target of antihypertensive therapy |
| Q36561841 | Cardinal role of the intrarenal renin-angiotensin system in the pathogenesis of diabetic nephropathy |
| Q46083552 | Cardio-renal protection with aliskiren, a direct renin inhibitor, in the ASPIRE HIGHER program |
| Q34779466 | Cardioprotective effect of fimasartan, a new angiotensin receptor blocker, in a porcine model of acute myocardial infarction |
| Q37950891 | Cardiorenal connection in chronic kidney disease. |
| Q37702722 | Cardiorenal interaction: appropriate treatment of cardiovascular risk factors to improve outcomes in chronic kidney disease |
| Q34572435 | Cardiorenal syndrome type 4-cardiovascular disease in patients with chronic kidney disease: epidemiology, pathogenesis, and management. |
| Q26767278 | Cardiovascular and Renal Outcomes of Renin-Angiotensin System Blockade in Adult Patients with Diabetes Mellitus: A Systematic Review with Network Meta-Analyses |
| Q41915019 | Cardiovascular and cerebrovascular outcomes in elderly hypertensive patients treated with either ARB or ACEI. |
| Q84563746 | Cardiovascular disease in patients with chronic kidney disease |
| Q37437174 | Cardiovascular implications of proteinuria: an indicator of chronic kidney disease |
| Q37454373 | Cardiovascular risk and management in chronic kidney disease |
| Q36603768 | Caring for patients with kidney disease: shifting the paradigm from evidence-based medicine to patient-centered care |
| Q64228115 | Catheter-based renal sympathetic denervation induces acute renal inflammation through activation of caspase-1 and NLRP3 inflammasome |
| Q90021693 | Change in albuminuria as a surrogate endpoint in chronic kidney disease |
| Q90021703 | Change in albuminuria as a surrogate endpoint in chronic kidney disease - Authors' reply |
| Q35108899 | Changes in albuminuria predict mortality and morbidity in patients with vascular disease |
| Q87393470 | Chapter 4: Blood pressure management in CKD ND patients with diabetes mellitus |
| Q87393485 | Chapter 8: Future directions and controversies |
| Q33591983 | Characterization and treatment of resistant hypertension |
| Q37202153 | Choice of ACE inhibitor combinations in hypertensive patients with type 2 diabetes: update after recent clinical trials |
| Q37695746 | Choosing Wisely: The Canadian Society of Nephrology's List of 5 Items Physicians and Patients Should Question |
| Q37778763 | Chronic Kidney Disease and Albuminuria in Arterial Hypertension |
| Q34631631 | Chronic kidney disease |
| Q36490142 | Chronic kidney disease and associated cardiovascular risk factors in chinese with type 2 diabetes |
| Q34921240 | Chronic kidney disease in the elderly: evaluation and management |
| Q51409315 | Chronic kidney disease prevention--a challenge for Asian countries: report of the Third Asian Forum of Chronic Kidney Disease Initiatives. |
| Q53519441 | Clinical Practice Guideline on management of patients with diabetes and chronic kidney disease stage 3b or higher (eGFR <45 mL/min). |
| Q34386587 | Clinical effectiveness of telmisartan alone or in combination therapy for controlling blood pressure and vascular risk in the elderly |
| Q35738903 | Clinical impacts of additive use of olmesartan in hypertensive patients with chronic heart failure: the supplemental benefit of an angiotensin receptor blocker in hypertensive patients with stable heart failure using olmesartan (SUPPORT) trial |
| Q33804805 | Clinical implications of the 2013 ESH/ESC hypertension guidelines: targets, choice of therapy, and blood pressure monitoring |
| Q45919060 | Clinical management of chronic kidney disease. |
| Q34736194 | Clinical practice guideline for the management of chronic kidney disease in patients infected with HIV: 2014 update by the HIV Medicine Association of the Infectious Diseases Society of America |
| Q38234930 | Clinical relevance of local Renin Angiotensin systems |
| Q30363683 | Clinical therapeutic strategies for early stage of diabetic kidney disease. |
| Q35705411 | Combination Treatment With Antihypertensive Agents Enhances the Effect of Qiliqiangxin on Chronic Pressure Overload-induced Cardiac Hypertrophy and Remodeling in Male Mice |
| Q41125760 | Combination antihypertensive therapy in clinical practice. The analysis of 1254 consecutive patients with uncontrolled hypertension. |
| Q37883908 | Combination inhibition of the renin-angiotensin system: is more better? |
| Q38947325 | Combination of ACE inhibitor with nicorandil provides further protection in chronic kidney disease |
| Q34418531 | Combination therapy an ACE inhibitor and an angiotensin receptor blocker for IgA nephropathy: a meta-analysis |
| Q37779805 | Combination therapy for hypertension: focus on high-dose olmesartan medoxomil (40 mg) plus hydrochlorothiazide |
| Q38425078 | Combination therapy in chronic kidney disease? |
| Q33980931 | Combination therapy in hypertension: An update |
| Q55165056 | Combination therapy in the treatment of hypertension. |
| Q34076439 | Combination therapy of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in chronic kidney disease |
| Q33166521 | Combined Angiotensin Receptor Modulation in the Management of Cardio-Metabolic Disorders |
| Q33830694 | Combining angiotensin receptor blockers with ACE inhibitors in elderly patients |
| Q42045329 | Combining angiotensin-receptor blockers with angiotensin-converting-enzyme inhibitors |
| Q34669789 | Common secondary causes of resistant hypertension and rational for treatment |
| Q36237809 | Comparative Efficacy and Safety of Antihypertensive Agents for Adult Diabetic Patients with Microalbuminuric Kidney Disease: A Network Meta-Analysis |
| Q33688308 | Comparative effectiveness of angiotensin-converting enzyme inhibitors versus angiotensin II receptor blockers for major renal outcomes in patients with diabetes: A 15-year cohort study |
| Q34380070 | Comparative effectiveness of renin-angiotensin system blockers and other antihypertensive drugs in patients with diabetes: systematic review and bayesian network meta-analysis |
| Q38502138 | Comparative efficacy and safety of blood pressure-lowering agents in adults with diabetes and kidney disease: a network meta-analysis |
| Q90578111 | Comparative proteinuria management of different angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for normotensive patients with CKD: a Bayesian network meta-analysis |
| Q38205213 | Comparative review of the blood pressure-lowering and cardiovascular benefits of telmisartan and perindopril |
| Q30360678 | Comparing angiotensin II receptor blockers on benefits beyond blood pressure |
| Q33764325 | Comparison of risk factors and guideline oriented prevention and therapy of diabetic retinopathy between type 2 diabetes patients undergoing laser therapy and type 2 diabetes outpatients |
| Q36466019 | Comprehensive approach to diabetic nephropathy |
| Q39331265 | Considerations and controversies in managing chronic kidney disease: An update |
| Q36599729 | Continuous renal replacement therapy versus furosemide for management of kidney impairment in heart transplant recipients with volume overload |
| Q34455207 | Contrast-associated AKI and use of cardiovascular medications after acute coronary syndrome |
| Q38939078 | Controversial issues in CKD clinical practice: position statement of the CKD-treatment working group of the Italian Society of Nephrology. |
| Q91963804 | Correlation between adverse events after drug treatment and the MDR1 C3435T polymorphism in advanced non-small cell lung cancer patients in an Asian population: a meta-analysis |
| Q50780550 | Cost-effectiveness of angiotensin-converting enzyme inhibitors versus angiotensin II receptor blockers as first-line treatment in autosomal dominant polycystic kidney disease. |
| Q35210587 | Current concepts in combination therapy for the treatment of hypertension: combined calcium channel blockers and RAAS inhibitors. |
| Q52886014 | DPP-4 inhibition on top of angiotensin receptor blockade offers a new therapeutic approach for diabetic nephropathy. |
| Q37087865 | Design of combination angiotensin receptor blocker and angiotensin-converting enzyme inhibitor for treatment of diabetic nephropathy (VA NEPHRON-D). |
| Q28387627 | Determination of an angiotensin II-regulated proteome in primary human kidney cells by stable isotope labeling of amino acids in cell culture (SILAC) |
| Q33647298 | Diabetes and cardiovascular disease: from evidence to clinical practice - position statement 2014 of Brazilian Diabetes Society. |
| Q40206755 | Diabetic Kidney Disease: Challenges, Progress, and Possibilities |
| Q45072634 | Diabetic Microvascular Disease: An Endocrine Society Scientific Statement |
| Q41993558 | Diabetic Nephropathy: a Tangled Web to Unweave |
| Q34609759 | Diabetic kidney disease and the cardiorenal syndrome: old disease, new perspectives |
| Q34429278 | Diabetic kidney disease: a clinical update from Kidney Disease: Improving Global Outcomes |
| Q27012546 | Diabetic kidney disease: a report from an ADA Consensus Conference |
| Q59220162 | Diabetic nephropathy |
| Q85278398 | Diabetic nephropathy |
| Q34228586 | Diabetic nephropathy for the primary care provider: new understandings on early detection and treatment |
| Q43116248 | Diabetic nephropathy: Aldosterone breakthrough in patients on an ACEI. |
| Q38150065 | Diabetic nephropathy: diagnosis and treatment |
| Q38338539 | Diabetic nephropathy: landmark clinical trials and tribulations |
| Q58712499 | Diabetic nephropathy: newer therapeutic perspectives |
| Q36589609 | Diabetic nephropathy: the role of inflammation in fibroblast activation and kidney fibrosis |
| Q61827265 | Diabetische Nephropathie – Update 2012 |
| Q39171913 | Diagnosis and Management of Type 2 Diabetic Kidney Disease |
| Q38553908 | Diagnosis and treatment of early renal disease in patients with type 2 diabetes mellitus: what are the clinical needs? |
| Q56686665 | Dialyse- und Ultrafiltrationsverfahren bei kardiorenalem Syndrom |
| Q49719393 | Dietary Approach to Stop Hypertension (DASH) diet and risk of renal function decline and all-cause mortality in renal transplant recipients. |
| Q40697633 | Dietary risk factors for incidence or progression of chronic kidney disease in individuals with type 2 diabetes in the European Union |
| Q38249494 | Dietary sodium restriction: a neglected therapeutic opportunity in chronic kidney disease |
| Q41652967 | Differential renal effects of candesartan at high and ultra-high doses in diabetic mice-potential role of the ACE2/AT2R/Mas axis |
| Q38599694 | Direct inhibition of plasmatic renin activity with aliskiren: a promising but under-investigated therapeutic option for non-diabetic glomerulonephritis |
| Q35000118 | Direct inhibition of renin: a physiological approach to treat hypertension and cardiovascular disease |
| Q38691518 | Direct renin inhibition prevents cardiac dysfunction in a diabetic mouse model: comparison with an angiotensin receptor antagonist and angiotensin-converting enzyme inhibitor |
| Q38088975 | Direct renin inhibition: extricating facts from façades |
| Q24198989 | Direct renin inhibitors for preventing the progression of diabetic kidney disease |
| Q37417576 | Direct renin inhibitors: ONTARGET for success? |
| Q39694133 | Discontinuation of angiotensin-converting enzyme inhibitors: a cohort study |
| Q37040190 | Do inhibitors of the rennin-angiotensin system prevent chronic kidney disease? |
| Q39356421 | Does a blood pressure J curve exist for patients with chronic kidney disease? |
| Q35771271 | Does antihypertensive treatment with renin-angiotensin system inhibitors prevent the development of diabetic kidney disease? |
| Q42670795 | Does cardiovascular protection translate into renal protection? |
| Q37110513 | Does losartan prevent progression of early diabetic nephropathy in American Indians with type 2 diabetes? |
| Q37012488 | Doubling of serum creatinine and the risk of cardiovascular outcomes in patients with chronic kidney disease and type 2 diabetes mellitus: a cohort study. |
| Q38654327 | Drug therapies to delay the progression of chronic kidney disease |
| Q35903126 | Drug-Induced Reduction in Albuminuria Is Associated with Subsequent Renoprotection: A Meta-Analysis |
| Q33674294 | Dual ACE-inhibition and AT1 receptor antagonism improves ventricular lusitropy without affecting cardiac fibrosis in the congenic mRen2.Lewis rat. |
| Q36701736 | Dual Blockade of the Renin-angiotensin-aldosterone System in Type 2 Diabetic Kidney Disease |
| Q86489714 | Dual RAAS blockade has dual effects on outcome |
| Q37776150 | Dual RAAS blockade is desirable in kidney disease: Con |
| Q85706075 | Dual RAS blockade-unresolved controversy? |
| Q38566920 | Dual Renin-Angiotensin-Aldosterone System Inhibition for the Treatment of Diabetic Kidney Disease: Adverse Effects and Unfulfilled Promise |
| Q37574913 | Dual blockade of the renin-angiotensin-aldosterone system: beyond the ACE inhibitor and angiotensin-II receptor blocker combination |
| Q37593689 | Dual renin-angiotensin system blockade in the ONTARGET study: clinically relevant risk for the kidney? |
| Q37053287 | Dual renin-angiotensin system inhibition for prevention of renal and cardiovascular events: do the latest trials challenge existing evidence? |
| Q38275264 | Dual renin-angiotensin-aldosterone blockade: promises and pitfalls |
| Q34604473 | Dual renin-angiotensin-aldosterone system blockade for diabetic kidney disease |
| Q37418807 | Early nephropathy in type 1 diabetes: the importance of early renal function decline |
| Q37728653 | Early recognition and prevention of chronic kidney disease |
| Q53484082 | Effect of Home Blood Pressure on Inducing Remission/Regression of Microalbuminuria in Patients With Type 2 Diabetes Mellitus. |
| Q36791014 | Effect of Intensive Versus Usual Blood Pressure Control on Kidney Function Among Individuals With Prior Lacunar Stroke: A Post Hoc Analysis of the Secondary Prevention of Small Subcortical Strokes (SPS3) Randomized Trial |
| Q92862014 | Effect of Renin-Angiotensin System Blockade on Mortality in Korean Hypertensive Patients with Proteinuria |
| Q37240299 | Effect of aliskiren on post-discharge outcomes among diabetic and non-diabetic patients hospitalized for heart failure: insights from the ASTRONAUT trial |
| Q37060053 | Effect of oral sodium bicarbonate supplementation on progression of chronic kidney disease in patients with chronic metabolic acidosis: study protocol for a randomized controlled trial (SoBic-Study). |
| Q49048863 | Effect of renin-angiotensin-aldosterone system blockade in adults with diabetes mellitus and advanced chronic kidney disease not on dialysis: a systematic review and meta-analysis |
| Q36195895 | Effects of ACEIs Versus ARBs on Proteinuria or Albuminuria in Primary Hypertension: A Meta-Analysis of Randomized Trials |
| Q38943637 | Effects of Intensive BP Control in CKD. |
| Q35971663 | Effects of Minocycline on Urine Albumin, Interleukin-6, and Osteoprotegerin in Patients with Diabetic Nephropathy: A Randomized Controlled Pilot Trial |
| Q37416423 | Effects of Ramipril and Telmisartan on Plasma Concentrations of Low Molecular Weight and Protein Thiols and Carotid Intima Media Thickness in Patients with Chronic Kidney Disease |
| Q36852567 | Effects of a new SGLT2 inhibitor, luseogliflozin, on diabetic nephropathy in T2DN rats |
| Q34405404 | Effects of add-on fluvastatin therapy in patients with chronic proteinuric nephropathy on dual renin-angiotensin system blockade: the ESPLANADE trial |
| Q47761508 | Effects of cilostazol and renin-angiotensin system (RAS) blockers on the renal disease progression of Korean patients: a retrospective cohort study. |
| Q37369476 | Effects of dual blockade of the renin-angiotensin system on renal and cardiovascular outcomes in type 2 diabetes with overt nephropathy and hypertension in the ORIENT: a post-hoc analysis (ORIENT-Hypertension). |
| Q35534210 | Effects of olmesartan on renal and cardiovascular outcomes in type 2 diabetes with overt nephropathy: a multicentre, randomised, placebo-controlled study. |
| Q99708016 | Effects of once-weekly subcutaneous semaglutide on kidney function and safety in patients with type 2 diabetes: a post-hoc analysis of the SUSTAIN 1-7 randomised controlled trials |
| Q28482185 | Effects of stimulation of soluble guanylate cyclase on diabetic nephropathy in diabetic eNOS knockout mice on top of angiotensin II receptor blockade |
| Q36764872 | Efficacy and safety of combined vs. single renin-angiotensin-aldosterone system blockade in chronic kidney disease: a meta-analysis |
| Q36567554 | Efficacy and safety of dual blockade of the renin-angiotensin system: meta-analysis of randomised trials |
| Q85940309 | Efficacy of add-on therapy of aliskiren to an angiotensin II receptor blocker on renal outcomes in advanced-stage chronic kidney disease: a prospective, randomized, open-label study |
| Q35826450 | Efficacy of aliskiren, compared with angiotensin II blockade, in slowing the progression of diabetic nephropathy in db/db mice: should the combination therapy be a focus? |
| Q86867761 | Efficacy, safety, and tolerability of antihypertensive therapy with aliskiren/amlodipine in clinical practice in Austria. The RALLY (Rasilamlo long lasting efficacy) study |
| Q39416346 | Efficiency and specificity of RAAS inhibitors in cardiovascular diseases: how to achieve better end-organ protection? |
| Q37962590 | Elevation of the antifibrotic peptide N-acetyl-seryl-aspartyl-lysyl-proline: a blood pressure-independent beneficial effect of angiotensin I-converting enzyme inhibitors |
| Q35905899 | Emerging drug combinations to optimize renovascular protection and blood pressure goals |
| Q34420383 | Emerging drugs for chronic kidney disease |
| Q37489497 | Emerging therapies for chronic kidney disease: what is their role? |
| Q38511505 | Emerging therapies in immunoglobulin A nephropathy |
| Q47140678 | Empagliflozin reduces albuminuria-a promise for better cardiorenal protection from the EMPA-REG OUTCOME trial. |
| Q37888664 | End-organ protection in patients with hypertension: focus on the role of angiotensin receptor blockers on renal function |
| Q41780685 | Endothelial cell autoantibodies in predicting declining renal function, end-stage renal disease, or death in adult type 2 diabetic nephropathy |
| Q37812341 | Endothelial damage and regeneration: the role of the renin-angiotensin-aldosterone system |
| Q37251105 | Endothelial-podocyte crosstalk: the missing link between endothelial dysfunction and albuminuria in diabetes |
| Q30251988 | Evaluation of Short-Term Changes in Serum Creatinine Level as a Meaningful End Point in Randomized Clinical Trials. |
| Q90484371 | Evaluation of preclinical safety profile of SPH3127, a direct renin inhibitor, after 28-day repeated oral administration in Sprague-Dawley rats and cynomolgus monkeys |
| Q35210531 | Evidence-based approach for managing hypertension in type 2 diabetes |
| Q38111134 | Evolving importance of kidney disease: from subspecialty to global health burden |
| Q38881453 | Exercise-induced albuminuria is related to metabolic syndrome. |
| Q37629831 | Exploring the optimal combination therapy in hypertensive patients with diabetes mellitus |
| Q38938623 | Focal Segmental Glomerulosclerosis |
| Q44551243 | Frictional purpuric eruption associated with angiotensin II receptor blockers |
| Q34391213 | From molecular signatures to predictive biomarkers: modeling disease pathophysiology and drug mechanism of action |
| Q90632374 | Glucose and Blood Pressure-Dependent Pathways-The Progression of Diabetic Kidney Disease |
| Q41145183 | Glycemic Control for Patients With Type 2 Diabetes Mellitus: Our Evolving Faith in the Face of Evidence |
| Q38734501 | Has RAAS Blockade Reached Its Limits in the Treatment of Diabetic Nephropathy? |
| Q37786566 | Have the renin-angiotensin-aldosterone system perturbations in cardiovascular disease been exhausted? |
| Q37776401 | Have we fallen off target with concerns surrounding dual RAAS blockade? |
| Q93539017 | High serum potassium levels after losartan can reflect more severe renal disease. Reply to Gonçalves AR, El Nahas AM [letter] |
| Q84395901 | High serum potassium levels after using losartan can reflect more severe renal disease |
| Q26799443 | Horizon 2020 in Diabetic Kidney Disease: The Clinical Trial Pipeline for Add-On Therapies on Top of Renin Angiotensin System Blockade |
| Q33876182 | Hotline update of clinical trials and registries presented at the American College of Cardiology Congress 2010: ACCORD, INVEST, NAVIGATOR, RACE II, SORT OUT III, CSP-474, DOSE, ASPIRE and more |
| Q38261883 | How do we prevent the vulnerable atherosclerotic plaque from rupturing? Insights from in vivo assessments of plaque, vascular remodeling, and local endothelial shear stress |
| Q52680286 | Hyperkalemia in the Hypertensive Patient. |
| Q35953909 | Hypertension Management in Diabetic Kidney Disease |
| Q37618602 | Hypertension and chronic kidney disease progression: why the suboptimal outcomes? |
| Q26768702 | Hypertension in Chronic Glomerulonephritis |
| Q37799425 | Hypertension in Special Populations: Chronic Kidney Disease, Organ Transplant Recipients, Pregnancy, Autonomic Dysfunction, Racial and Ethnic Populations |
| Q37253892 | Hypertension in diabetes: a call to action |
| Q37827620 | Hypertension in diabetic nephropathy: epidemiology, mechanisms, and management |
| Q37593676 | Hypertension in patients with chronic kidney disease |
| Q35213902 | Hypertension in people with type 2 diabetes: Update on pharmacologic management. |
| Q37868721 | Hypertension treatment update: focus on direct renin inhibition |
| Q37593674 | Hypertension: issues in control and resistance |
| Q34131899 | Hypertensive nephropathy: prevention and treatment recommendations |
| Q26765228 | Hyporeninemic hypoaldosteronism and diabetes mellitus: Pathophysiology assumptions, clinical aspects and implications for management |
| Q37886063 | Identification and management of albuminuria in the primary care setting |
| Q38391129 | Impact of telmisartan in modifying vascular risk |
| Q37455654 | Implications of recent clinical trials on pay-for-performance |
| Q38707728 | Improvement of cardiovascular remodelling by chymase inhibitor |
| Q28080717 | Improvements in the Management of Diabetic Nephropathy |
| Q37427251 | Improving microvascular outcomes in patients with diabetes through management of hypertension |
| Q38068099 | Improving the efficacy of RAAS blockade in patients with chronic kidney disease |
| Q37051619 | In patients with type 1 diabetes and new-onset microalbuminuria the development of advanced chronic kidney disease may not require progression to proteinuria. |
| Q45701778 | Incidence, Severity, and Outcomes of AKI Associated with Dual Renin-Angiotensin System Blockade. |
| Q36581013 | Influence of Renal Insufficiency on the Prescription of Evidence-Based Medicines in Patients With Coronary Artery Disease and Its Prognostic Significance: A Retrospective Cohort Study |
| Q89835347 | Inhibition of Angiotensin-Converting Enzyme Ameliorates Renal Fibrosis by Mitigating DPP-4 Level and Restoring Antifibrotic MicroRNAs |
| Q37353859 | Inhibition of the renin-angiotensin system: is more better? |
| Q92669472 | Innate immunity in diabetic kidney disease |
| Q39255681 | Insights into autosomal dominant polycystic kidney disease by quantitative mass spectrometry-based proteomics. |
| Q61708125 | Is dual RAAS blockade useful in diabetic nephropathy? |
| Q42920897 | Is it AKI or nonrecovery of renal function that is important for long-term outcomes? |
| Q38076689 | Is there benefit in dual renin-angiotensin-aldosterone system blockade? No, yes and maybe: a guide for the perplexed |
| Q52685042 | JAK1/JAK2 inhibition by baricitinib in diabetic kidney disease: results from a Phase 2 randomized controlled clinical trial. |
| Q34245670 | Juxtaglomerular apparatus hyperplasia under dual angiotensin blockade. A footprint of adequate RAS inhibition or a concern for renal fibrosis? |
| Q37593665 | KDOQI US commentary on the 2012 KDIGO clinical practice guideline for management of blood pressure in CKD. |
| Q56686664 | Kardiorenales Syndrom |
| Q84896853 | Left ventricular mass index as a predictor of new-onset microalbuminuria in hypertensive subjects: a prospective study |
| Q37576119 | Lessons learned from the ONTARGET and TRANSCEND trials |
| Q33574532 | Lipid, blood pressure and kidney update 2013. |
| Q57040510 | Lisinopril versus lisinopril and losartan for mild childhood IgA nephropathy: a randomized controlled trial (JSKDC01 study) |
| Q37648704 | Lower estimated GFR and higher albuminuria are associated with adverse kidney outcomes. A collaborative meta-analysis of general and high-risk population cohorts |
| Q83393056 | Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality. A collaborative meta-analysis of high-risk population cohorts |
| Q93536412 | L’hypertension chez les diabétiques de type 2: Mise à jour sur le traitement pharmacologique |
| Q30240155 | Management Protocols of stable coronary artery disease in India: Executive summary |
| Q30353386 | Management of Diabetic Nephropathy in the Elderly: Special Considerations. |
| Q26740477 | Management of Membranous Nephropathy in Western Countries |
| Q37869806 | Management of blood pressure in patients with diabetes |
| Q27009775 | Management of diabetic kidney disease: Recent advances |
| Q37762263 | Management of high blood pressure in type 2 diabetes: perindopril/indapamide fixed-dose combination and the ADVANCE trial [corrected]. |
| Q37304418 | Management of patients with resistant hypertension: current treatment options |
| Q99403175 | Management of proteinuria: blockade of the renin-angiotensin-aldosterone system |
| Q44639103 | Management of renin-angiotensin system blockade in patients with chronic kidney disease under specialist care. Retrospective cross-sectional study. |
| Q30239853 | Management standards for stable coronary artery disease in India |
| Q37892340 | Managing kidney disease with blood-pressure control |
| Q37763195 | Manidipine treatment in patients with albuminuria not sufficiently reduced with renin-angiotensin system blockers |
| Q44871811 | Mapping of molecular pathways, biomarkers and drug targets for diabetic nephropathy |
| Q37604882 | Mechanisms of the cardiorenal syndromes |
| Q90397654 | Medication Prescribing Quality in Australian Primary Care Patients with Chronic Kidney Disease |
| Q28085248 | Meta-Analysis of the Effect of Dietary Sodium Restriction with or without Concomitant Renin-Angiotensin-Aldosterone System-Inhibiting Treatment on Albuminuria |
| Q28748219 | Meta-analysis of combined therapy with angiotensin receptor antagonists versus ACE inhibitors alone in patients with heart failure |
| Q38206640 | Microalbuminuria: target for renoprotective therapy PRO. |
| Q38119861 | Mineralocorticoid receptor activation as an etiological factor in kidney diseases |
| Q37998573 | Mineralocorticoid receptor antagonist for renal protection |
| Q47774395 | Modifiable lifestyle and social factors affect chronic kidney disease in high-risk individuals with type 2 diabetes mellitus |
| Q37566053 | Monitoring and managing urinary albumin excretion: practical advice for primary care clinicians |
| Q33159154 | Morbidity and Mortality of Orthostatic Hypotension: Implications for Management of Cardiovascular Disease |
| Q44034435 | Mortality and morbidity in relation to changes in albuminuria, glucose status and systolic blood pressure: an analysis of the ONTARGET and TRANSCEND studies |
| Q36497887 | Multicentre randomized controlled trial of angiotensin-converting enzyme inhibitor/angiotensin receptor blocker withdrawal in advanced renal disease: the STOP-ACEi trial |
| Q37503827 | Multiple renin-angiotensin-aldosterone-blocking agents in heart failure: how much is too much? |
| Q24618843 | My approach to the treatment of scleroderma |
| Q37780943 | National Kidney Foundation consensus conference on cardiovascular and kidney diseases and diabetes risk: an integrated therapeutic approach to reduce events |
| Q38241522 | Neprilysin inhibition in chronic kidney disease |
| Q34530891 | Network modeling reveals steps in angiotensin peptide processing. |
| Q38120300 | Neurohormonal interactions on the renal oxygen delivery and consumption in haemorrhagic shock-induced acute kidney injury. |
| Q47583196 | New clinical concepts after the ONTARGET trial |
| Q42910369 | New modalities of renin-angiotensin system inhibition: Renin inhibitors and active immunization against angiotensin II |
| Q37741787 | New pharmacological treatments for improving renal outcomes in diabetes |
| Q37893014 | New roles for renin and prorenin in heart failure and cardiorenal crosstalk |
| Q64230728 | New strategies and perspectives on managing IgA nephropathy |
| Q24235956 | Non-immunosuppressive treatment for IgA nephropathy |
| Q36417881 | Normal 25-Hydroxyvitamin D Levels Are Associated with Less Proteinuria and Attenuate Renal Failure Progression in Children with CKD. |
| Q35953867 | Novel Therapies for Diabetic Kidney Disease: Storied Past and Forward Paths |
| Q37219043 | Novel drugs and intervention strategies for the treatment of chronic kidney disease |
| Q52573051 | Novel inhibitors of the cellular RAS components, Poricoic acids, target Smad3 phosphorylation and Wnt/β-catenin pathway against renal fibrosis. |
| Q35878999 | Novel urinary protein biomarkers predicting the development of microalbuminuria and renal function decline in type 1 diabetes |
| Q38774339 | Nrf2 activators as attractive therapeutics for diabetic nephropathy. |
| Q46134728 | ONTARGET, TRANSCEND and PROFESS--clarifying, confusing or misleading? |
| Q83462152 | ONTARGET: does dual blockade of the renin-angiotensin system provide more effective cardiovascular and renal protection in patients at high cardiovascular risk? |
| Q42946303 | Of fads, fashion, surrogate endpoints and dual RAS blockade |
| Q35085669 | Olmesartan vs. ramipril in elderly hypertensive patients: review of data from two published randomized, double-blind studies. |
| Q37368669 | On target to dual block RAS? |
| Q37766844 | Optimal antagonism of the Renin-Angiotensin-aldosterone system: do we need dual or triple therapy? |
| Q46084787 | Optimal dosing of renin-angiotensin-aldosterone system blockers for renal protection: a solved issue? |
| Q57180785 | Optimal medical treatment of hypertension in patients with coronary artery disease |
| Q37828455 | Optimal therapy in hypertensive subjects with diabetes mellitus. |
| Q37593679 | Outcomes of antiproteinuric RAAS blockade: high-dose compared with dual therapy |
| Q50998627 | Outpatient management of chronic heart failure. |
| Q37375567 | Oxidative stress/angiotensinogen/renin-angiotensin system axis in patients with diabetic nephropathy |
| Q57701985 | PPAR 2 P12A polymorphism and albuminuria in patients with type 2 diabetes: a meta-analysis of case-control studies |
| Q37861885 | Pathophysiology, prevention and management of chronic kidney disease in the hypertensive patient with diabetes mellitus. |
| Q64084205 | Patient and disease characteristics of type-2 diabetes patients with or without chronic kidney disease: an analysis of the German DPV and DIVE databases |
| Q38886136 | Patient-Centred Care of Older Adults With Cardiovascular Disease and Multiple Chronic Conditions |
| Q42864618 | Perindopril for improving cardiovascular events |
| Q35012444 | Pirfenidone for diabetic nephropathy |
| Q37826797 | Pleiotropic effects of angiotensin receptor blockers: addressing comorbidities by optimizing hypertension therapy |
| Q37553108 | Potassium handling with dual renin-angiotensin system inhibition in diabetic nephropathy |
| Q37095324 | Preclinical cardiorenal interrelationships in essential hypertension |
| Q28566503 | Prescription of renin-angiotensin system blockers and risk of acute kidney injury: a population-based cohort study |
| Q37069905 | Prevalence and Management of Diabetic Nephropathy in Western Countries |
| Q36249768 | Prevalence and risk factors for cardiovascular disease among chronic kidney disease patients: results from the Chinese cohort study of chronic kidney disease (C-STRIDE). |
| Q38048843 | Preventing cardiovascular events with angiotensin II receptor blockers: a closer look at telmisartan and valsartan |
| Q38014435 | Prevention of diabetic complications by activation of Nrf2: diabetic cardiomyopathy and nephropathy |
| Q36094286 | Prevention of microalbuminuria using early intervention with renin-angiotensin system inhibitors in patients with type 2 diabetes: A systematic review. |
| Q37285574 | Primary and secondary prevention of cardiovascular diseases: a practical evidence-based approach |
| Q37783417 | Progress Toward Novel Treatments for Chronic Kidney Disease |
| Q46750354 | Progressive chronic kidney disease in primary care: modifiable risk factors and predictive model |
| Q86726990 | Prospective randomized study of the tolerability and efficacy of combination therapy for hypertensive chronic kidney disease: results of the PROTECT-CKD study |
| Q55053682 | Protection Against Nephropathy in Diabetes with Atorvastatin (PANDA): a randomized double-blind placebo-controlled trial of high- vs. low-dose atorvastatin(1). |
| Q37591933 | Proteinuria and clinical outcomes in hypertensive patients |
| Q37414937 | Proteinuria and its relation to cardiovascular disease |
| Q83575095 | Proteinuria as a surrogate end point--more data are needed |
| Q38028890 | Proteinuria in the elderly: evaluation and management |
| Q45917252 | Proteinuria: Is the ONTARGET renal substudy actually off target? |
| Q43754866 | Proteinuria: does vitamin D treatment improve outcomes in CKD? |
| Q37871572 | Proteomics in chronic kidney disease: The issues clinical nephrologists need an answer for. |
| Q37154147 | Quantification of angiotensin II-regulated proteins in urine of patients with polycystic and other chronic kidney diseases by selected reaction monitoring. |
| Q39988795 | RAS blockade for every diabetic patient: pro and con. |
| Q36551388 | RAS-Mediated Adaptive Mechanisms in Cardiovascular Tissues: Confounding Factors of RAS Blockade Therapy and Alternative Approaches |
| Q35790521 | Randomized Placebo-Controlled EPPIC Trials of AST-120 in CKD. |
| Q45741432 | Randomized study of antihypertensive efficacy and safety of combination aliskiren/valsartan vs valsartan monotherapy in hypertensive participants with type 2 diabetes mellitus |
| Q33453707 | Rapid and Low-Cost CRP Measurement by Integrating a Paper-Based Microfluidic Immunoassay with Smartphone (CRP-Chip) |
| Q42272174 | Rationale and trial design of Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON). |
| Q37798001 | Rationale for the use of a fixed-dose combination in the management of hypertension: efficacy and tolerability of lercanidipine/enalapril. |
| Q40030390 | Re-examining RAS-blocking treatment regimens for abrogating progression of chronic kidney disease |
| Q56970710 | Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document |
| Q35015215 | Reappraisal of role of angiotensin receptor blockers in cardiovascular protection |
| Q42712761 | Rebuttal of the Pro View: Albuminuria Is an Appropriate Therapeutic Target in Patients with CKD. |
| Q26745900 | Recent advances in managing and understanding diabetic nephropathy |
| Q37629835 | Recent changes in the landscape of combination RAS blockade |
| Q34887952 | Recognition, pathogenesis, and treatment of different stages of nephropathy in patients with type 2 diabetes mellitus |
| Q26851307 | Reducing cardiorenal risk through combination therapy with a direct renin inhibitor |
| Q37862922 | Reducing cardiovascular events and end-organ damage in patients with hypertension: new considerations |
| Q93609101 | References |
| Q43059625 | Remote ischemic preconditioning for renal protection during elective open infrarenal abdominal aortic aneurysm repair: randomized controlled trial |
| Q28082365 | Renal autoregulation in health and disease |
| Q34006930 | Renal denervation after Symplicity HTN-3: an update |
| Q36713381 | Renal denervation: ultima ratio or standard in treatment-resistant hypertension |
| Q37364926 | Renal effects of aliskiren compared with and in combination with irbesartan in patients with type 2 diabetes, hypertension, and albuminuria |
| Q37919547 | Renal endpoints in renal and cardiovascular randomized clinical trials: time for a consensus? |
| Q38018816 | Renal function trajectory is more important than chronic kidney disease stage for managing patients with chronic kidney disease |
| Q43702577 | Renal outcomes in the ONTARGET study |
| Q82907954 | Renal outcomes in the ONTARGET study |
| Q94834787 | Renal outcomes in the ONTARGET study |
| Q94834821 | Renal outcomes in the ONTARGET study |
| Q34221460 | Renal protection in diabetes: lessons from ONTARGET® |
| Q35728190 | Renin inhibitors in diabetes and hypertension: an update |
| Q36329456 | Renin-Angiotensin-Aldosterone System Blockade in Diabetic Nephropathy. Present Evidences |
| Q28308222 | Renin-Angiotensin-aldosterone system in diabetes and hypertension |
| Q46426114 | Renin-angiotensin blockade and kidney disease |
| Q38137851 | Renin-angiotensin system blocking drugs. |
| Q50101784 | Renin-angiotensin-aldosterone system activation in long-standing type 1 diabetes. |
| Q44474346 | Renin-angiotensin-aldosterone system blockade and urinary albumin excretion in community-based patients with Type 2 diabetes: the Fremantle Diabetes Study. |
| Q34124779 | Renin-angiotensin-aldosterone system blockade for cardiovascular diseases: current status |
| Q38777543 | Renin-angiotensin-aldosterone system blockade in chronic kidney disease: current strategies and a look ahead |
| Q37505849 | Renin-angiotensin-aldosterone system blockade in diabetes: role of direct renin inhibitors |
| Q37802083 | Renin-angiotensin-aldosterone system blockade in high-risk hypertensive patients: current approaches and future trends |
| Q35210518 | Renoprotection, renin inhibition, and blood pressure control: the impact of aliskiren on integrated blood pressure control |
| Q35571854 | Renoprotective effects of atorvastatin compared with pravastatin on progression of early diabetic nephropathy |
| Q37895676 | Renoprotective effects of benazepril: current perspective |
| Q36004330 | Renoprotective effects of combined SGLT2 and ACE inhibitor therapy in diabetic Dahl S rats |
| Q28583340 | Renoprotective effects of long-term oral nicotine in a rat model of spontaneous proteinuria |
| Q38149854 | Renoprotective strategies in lupus nephritis: beyond immunosuppression. |
| Q35534677 | Resistant hypertension: an approach to management in primary care. |
| Q45058890 | Resting heart rate is associated with renal disease outcomes in patients with vascular disease: results of the ONTARGET and TRANSCEND studies. |
| Q37167526 | Results of the ONTARGET and TRANSCEND studies: an update and discussion. |
| Q36082302 | Retarding the progression of chronic kidney disease with renin angiotensin system blockade |
| Q38123092 | Review of direct renin inhibition by aliskiren |
| Q37415058 | Review: renal protection by inhibition of the renin-angiotensin-aldosterone system |
| Q47669329 | Revisiting RAAS blockade in CKD with newer potassium-binding drugs |
| Q35691583 | Risk Prediction for Early CKD in Type 2 Diabetes |
| Q37330330 | Risk factors for cyclosporin A nephrotoxicity in children with steroid-dependant nephrotic syndrome |
| Q35115546 | Role of angiotensin converting enzyme inhibitors and angiotensin receptor blockers in hypertension of chronic kidney disease and renoprotection. Study results |
| Q37629832 | Role of angiotensin receptor blockers in diabetes: implications of recent clinical trials |
| Q38048939 | Role of single-pill combination therapy in optimizing blood pressure control in high-risk hypertension patients and management of treatment-related adverse events |
| Q30429844 | Role of the intrarenal renin-angiotensin-aldosterone system in chronic kidney disease |
| Q24650910 | Safety and efficacy of enzyme replacement therapy in the nephropathy of Fabry disease |
| Q38957950 | Scleroderma renal crisis and renal involvement in systemic sclerosis |
| Q42045011 | Selective stimulation of VEGFR2 accelerates progressive renal disease |
| Q34625011 | Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial |
| Q89882591 | Serum Activin A Levels and Renal Outcomes After Coronary Angiography |
| Q42624224 | Serum potassium in dual renin-angiotensin-aldosterone system blockade |
| Q41932280 | Severe hepatic encephalopathy in a patient with liver cirrhosis after administration of angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker combination therapy: a case report |
| Q97547914 | Should Angiotensin-Converting Enzyme Inhibitors ever Be Used for the Management of Hypertension? |
| Q37593682 | Should albuminuria be a focus of antihypertensive therapy goals? |
| Q38015765 | Should two-drug initial therapy for hypertension be recommended for all patients? |
| Q85046099 | Should we modify our therapeutic behavior as a consequence of the 2009 revision of the ESH/ESC guidelines for the management of arterial hypertension |
| Q33873241 | Slowing progression of chronic kidney disease |
| Q37676827 | Slowing the progression of chronic kidney disease |
| Q38737061 | Special considerations for the treatment of chronic kidney disease in the elderly. |
| Q34587130 | Study design of DIACORE (DIAbetes COhoRtE) - a cohort study of patients with diabetes mellitus type 2. |
| Q39165618 | Subclinical Kidney Damage in Hypertensive Patients: A Renal Window Opened on the Cardiovascular System. Focus on Microalbuminuria. |
| Q45921075 | Successful effect of triple blockade of renin-angiotensin-aldosterone system on massive proteinuria in a patient with chronic kidney disease. |
| Q33994970 | Systematic review of the effect of telmisartan on insulin sensitivity in hypertensive patients with insulin resistance or diabetes |
| Q45141864 | Systemic hemodynamic function in humans with type 1 diabetes treated with protein kinase Cβ inhibition and renin-angiotensin system blockade: a pilot study |
| Q35786928 | TElmisartan in the management of abDominal aortic aneurYsm (TEDY): The study protocol for a randomized controlled trial |
| Q53860769 | Tacrolimus-induced hypertension and nephrotoxicity in Fawn-Hooded rats are attenuated by dual inhibition of renin-angiotensin system. |
| Q37368101 | Target-organ protection with combination renin-angiotensin-system blockade. |
| Q35923433 | Targeting tubulointerstitial remodeling in proteinuric nephropathy in rats |
| Q37960631 | Telmisartan for the reduction of cardiovascular morbidity and mortality |
| Q38111434 | Telmisartan/Hydrochlorothiazide combination therapy for the treatment of hypertension: a pooled analysis in older and younger patients |
| Q37866755 | Telmisartan: a review of its use in cardiovascular disease prevention |
| Q37955284 | Telmisartan: just an antihypertensive agent? A literature review |
| Q34607311 | The 2009 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 2--therapy |
| Q36259972 | The Impact of Renin-Angiotensin System Blockade on Renal Outcomes and Mortality in Pre-Dialysis Patients with Advanced Chronic Kidney Disease. |
| Q92377672 | The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2019) |
| Q63681844 | The Long-Term Impact of Renin-Angiotensin System (RAS) Inhibition on Cardiorenal Outcomes (LIRICO): A Randomized, Controlled Trial |
| Q37741783 | The RAAS in the pathogenesis and treatment of diabetic nephropathy |
| Q43746740 | The administration of pitavastatin augments creatinine clearance associated with reduction in oxidative stress parameters: acute and early effects |
| Q57463189 | The benefits of angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers combined with calcium channel blockers on metabolic, renal, and cardiovascular outcomes in hypertensive patients: a meta-analysis |
| Q38224257 | The biological significance of angiotensin-converting enzyme inhibition to combat kidney fibrosis |
| Q37142744 | The bone morphogenic protein inhibitor, noggin, reduces glycemia and vascular inflammation in db/db mice |
| Q35001942 | The comparative efficacy and safety of the angiotensin receptor blockers in the management of hypertension and other cardiovascular diseases |
| Q37623107 | The current state of RAAS blockade in the treatment of hypertension and proteinuria |
| Q41989543 | The diabetes pandemic suggests unmet needs for 'CKD with diabetes' in addition to 'diabetic nephropathy'-implications for pre-clinical research and drug testing |
| Q34135967 | The differential effect of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers with respect to foot ulcer and limb amputation in those with diabetes |
| Q38168046 | The effect of RAAS blockade on the progression of diabetic nephropathy |
| Q38050872 | The effect of antihypertensive drugs on chronic kidney disease: a comprehensive review |
| Q34122611 | The effect of combination treatment with aliskiren and blockers of the renin-angiotensin system on hyperkalaemia and acute kidney injury: systematic review and meta-analysis |
| Q36334722 | The effect of direct renin inhibition alone and in combination with ACE inhibition on endothelial function, arterial stiffness, and renal function in type 1 diabetes |
| Q37559421 | The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus |
| Q44532842 | The effect of ramipril and telmisartan on serum potassium and its association with cardiovascular and renal events: results from the ONTARGET trial |
| Q57701326 | The establishment and validation of novel therapeutic targets to retard progression of chronic kidney disease |
| Q38605695 | The glycocalyx--linking albuminuria with renal and cardiovascular disease |
| Q37681363 | The goal of blood pressure in the hypertensive patient with diabetes is defined: now the challenge is go from recommendations to practice |
| Q34439098 | The growth of acute kidney injury: a rising tide or just closer attention to detail? |
| Q38174491 | The gut-renal axis: do incretin-based agents confer renoprotection in diabetes? |
| Q35760302 | The kidney in type 2 diabetes therapy |
| Q37466880 | The management of hypertension with angiotensin receptor blockers in special populations |
| Q38374536 | The necessity and effectiveness of mineralocorticoid receptor antagonist in the treatment of diabetic nephropathy |
| Q38005037 | The neurohormonal network in the RAAS can bend before breaking |
| Q39813086 | The one-two punch: knocking out angiotensin II in the heart. |
| Q37788947 | The progressive pathway of microalbuminuria: from early marker of renal damage to strong cardiovascular risk predictor |
| Q37158159 | The renin-angiotensin system modulates inflammatory processes in atherosclerosis: evidence from basic research and clinical studies |
| Q37874892 | The role of angiotensin receptor blockers in diabetic nephropathy |
| Q37918526 | The role of direct renin inhibition in clinical practice: focus on combination therapy |
| Q37519741 | The role of fixed-dose combinations in the management of hypertension: focus on lercanidipine-enalapril |
| Q41206891 | The role of renin angiotensin system inhibition in kidney repair. |
| Q37980260 | The role of renin inhibition in treating the hypertensive patient with diabetes: a summary of preclinical and clinical evidence |
| Q36532932 | The role of type 1 angiotensin receptors on T lymphocytes in cardiovascular and renal diseases |
| Q34765075 | The safety of combining angiotensin-converting-enzyme inhibitors with angiotensin-receptor blockers in elderly patients: a population-based longitudinal analysis |
| Q38209811 | Therapeutic approaches to diabetic nephropathy--beyond the RAS. |
| Q37449207 | Therapeutic approaches to slowing the progression of diabetic nephropathy - is less best? |
| Q30362729 | Therapeutic management of diabetic kidney disease. |
| Q27007027 | Therapeutic modalities in diabetic nephropathy: standard and emerging approaches. |
| Q36327950 | Therapeutic perspective: starting an angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker in a diabetic patient |
| Q38605099 | Therapies on the Horizon for Diabetic Kidney Disease. |
| Q37973302 | Time to differentiate 'decreased kidney function' from 'kidney disease': towards improving the definition of chronic kidney disease |
| Q38098108 | To RAS or not to RAS? The evidence for and cautions with renin-angiotensin system inhibition in patients with diabetic kidney disease. |
| Q38057913 | Tolerating increases in the serum creatinine following aggressive treatment of chronic kidney disease, hypertension and proteinuria: pre-renal success |
| Q27694623 | Treatment of chronic kidney disease |
| Q33907249 | Treatment of diabetic kidney disease: current and future targets |
| Q37519704 | Treatment strategies for peripheral artery disease |
| Q34609043 | Trends in co-prescribing of angiotensin converting enzyme inhibitors and angiotensin receptor blockers in Ireland |
| Q36297539 | Twenty years after ACEIs and ARBs: emerging treatment strategies for diabetic nephropathy |
| Q26798326 | Update on Prevention of Cardiovascular Disease in Adults With Type 2 Diabetes Mellitus in Light of Recent Evidence: A Scientific Statement From the American Heart Association and the American Diabetes Association |
| Q27687851 | Update on Prevention of Cardiovascular Disease in Adults With Type 2 Diabetes Mellitus in Light of Recent Evidence: A Scientific Statement From the American Heart Association and the American Diabetes Association. |
| Q38492248 | Update on blood pressure control and renal outcomes in diabetes mellitus |
| Q37783418 | Uremia (End-Stage Renal Disease): How Cost-Effective are Preventive Strategies? |
| Q36236725 | Urinary angiotensinogen as a novel early biomarker of intrarenal renin-angiotensin system activation in experimental type 1 diabetes |
| Q64054148 | Urinary angiotensinogen level is associated with potassium homeostasis and clinical outcome in patients with polycystic kidney disease: a prospective cohort study |
| Q46159940 | Urine RAS components in mice and people with type 1 diabetes and chronic kidney disease |
| Q58123861 | Use of Antihypertensive Agents and Association With Risk of Adverse Outcomes in Chronic Kidney Disease: Focus on Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers |
| Q37054912 | Using extracellular biomarkers for monitoring efficacy of therapeutics in cancer patients: an update |
| Q35210583 | Valsartan combination therapy in the management of hypertension - patient perspectives and clinical utility |
| Q36801566 | Vitamin D analogues to target residual proteinuria: potential impact on cardiorenal outcomes |
| Q40168862 | Vitamin D receptor activation with calcitriol for reducing urinary angiotensinogen in patients with type 2 diabetic chronic kidney disease |
| Q35959046 | What is a preferred angiotensin II receptor blocker-based combination therapy for blood pressure control in hypertensive patients with diabetic and non-diabetic renal impairment? |
| Q37910062 | What is the role of direct renin inhibitors in the treatment of the hypertensive diabetic patient? |
| Q37263019 | What should be the blood pressure target for patients with chronic kidney disease? |
| Q37721287 | When to initiate ACEI/ARB therapy in patients with type 1 and 2 diabetes |
| Q37803235 | Which antihypertensive drugs are the most nephroprotective and why? |
| Q36630037 | Wnt/β-catenin signaling and renin-angiotensin system in chronic kidney disease |
| Q38237435 | Zofenopril plus hydrochlorothiazide combination in the treatment of hypertension: an update. |
| Q83200607 | [Albuminuria : prognostic marker or therapeutic goal?] |
| Q51177575 | [Analysis of the rational use of anti-hypertensives in the Murcia (Spain) region]. |
| Q53600013 | [Antihypertensive drug therapy : Where do we stand?]. |
| Q85725369 | [Antihypertensive therapy in diabetes mellitus - 2012 guidelines of the Austrian Diabetes Association] |
| Q89134616 | [Antihypertensive therapy in diabetes mellitus: Guidelines of the Austrian Diabetes Association 2016] |
| Q83941120 | [Cardiorenal syndrome] |
| Q82770377 | [Debate concerning the optimal blockage of the renin-angiotensin system] |
| Q53620509 | [Diabetic kidney disease - Update 2016]. |
| Q84952346 | [Diabetic nephropathy] |
| Q51157081 | [Fixed drug combinations in hypertension: a budget impact analysis for the Spanish Health System on the marketing of a fixed combination of olmesartan/amlodipine]. |
| Q83552993 | [Kidney and hypertension] |
| Q83767359 | [Nephroprotection and vascular risk: prevention of renal damage in hypertension] |
| Q46020740 | [Optimal therapy of diabetic nephropathy: AVOID Study (Aliskiren in the evaluation of proteinuria in diabetes)]. |
| Q83879584 | [Treating high blood pressure in kidney patients: evidence and implications] |
| Q82734949 | [What has changed in the current management of hypertension from the renal point of view?] |
| Q33706716 | alpha- and beta-Adducin polymorphisms affect podocyte proteins and proteinuria in rodents and decline of renal function in human IgA nephropathy |
| Q57750302 | ‘To block or not to block’; whether to continue renin–angiotensin–aldosterone system blockade in advanced chronic kidney disease |
Search more.